BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $VIR readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07128550-pcd@datacutoff.com
DTSTAMP:20261120T191202Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Tobevibart readout (P3) · Vir Biotechnology\, Inc. $VIR
DESCRIPTION:A Study to Evaluate Tobevibart+Elebsiran in Participants With C
 hronic HDV Infection Not Virologically Suppressed With Bulevirtide\n\nPrim
 ary completion date: 2026-12 (estimated) — month only\, shown on the 1st
 \nPhase 3 · Infectious · Viral Hepatitis\nEnrollment: 150 · Sites: 38\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT07128550\nhttps://clinicaltrials.gov/study/NCT07128550
URL:https://datacutoff.com/radar.html?nct=NCT07128550
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
